136 related articles for article (PubMed ID: 1963047)
1. The T-lymphocyte response to varicella-zoster viral proteins.
Arvin AM; Koropchak CM; Sharp M; Bergen R; Diaz PS
Adv Exp Med Biol; 1990; 278():71-81. PubMed ID: 1963047
[No Abstract] [Full Text] [Related]
2. Cell-mediated immunity to varicella-zoster virus.
Arvin AM
J Infect Dis; 1992 Aug; 166 Suppl 1():S35-41. PubMed ID: 1320649
[TBL] [Abstract][Full Text] [Related]
3. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine.
Sharp M; Terada K; Wilson A; Nader S; Kinchington PE; Ruyechan WT; Hay J; Arvin AM
J Infect Dis; 1992 May; 165(5):852-8. PubMed ID: 1314871
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content.
Bergen RE; Diaz PS; Arvin AM
J Infect Dis; 1990 Nov; 162(5):1049-54. PubMed ID: 2172393
[TBL] [Abstract][Full Text] [Related]
5. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus.
Bergen RE; Sharp M; Sanchez A; Judd AK; Arvin AM
Viral Immunol; 1991; 4(3):151-66. PubMed ID: 1725699
[TBL] [Abstract][Full Text] [Related]
6. Ability of yeast Ty-VLPs (virus-like particles) containing varicella-zoster virus (VZV)gE and assembly protein fragments to induce in vitro proliferation of human lymphocytes from VZV immune patients.
Welsh MD; Harper DR; Garcia-Valcarcel M; Fowler WJ; Aitken C; Jeffries DJ; Layton GT
J Med Virol; 1999 Sep; 59(1):78-83. PubMed ID: 10440812
[TBL] [Abstract][Full Text] [Related]
7. Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine.
Diaz PS; Smith S; Hunter E; Arvin AM
J Infect Dis; 1988 Dec; 158(6):1245-52. PubMed ID: 2848901
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation.
Jacquet A; Haumont M; Massaer M; Garcia L; Mazzu P; Daminet V; Grégoire D; Jacobs P; Bollen A
Vaccine; 2002 Feb; 20(11-12):1593-602. PubMed ID: 11858867
[TBL] [Abstract][Full Text] [Related]
9. Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes.
Hayward A; Giller R; Levin M
Viral Immunol; 1989; 2(3):175-84. PubMed ID: 2483504
[TBL] [Abstract][Full Text] [Related]
10. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype.
Arvin AM; Sharp M; Smith S; Koropchak CM; Diaz PS; Kinchington P; Ruyechan W; Hay J
J Immunol; 1991 Jan; 146(1):257-64. PubMed ID: 1670603
[TBL] [Abstract][Full Text] [Related]
11. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62.
Lowry PW; Solem S; Watson BN; Koropchak CM; Thackray HM; Kinchington PR; Ruyechan WT; Ling P; Hay J; Arvin AM
J Gen Virol; 1992 Apr; 73 ( Pt 4)():811-9. PubMed ID: 1321876
[TBL] [Abstract][Full Text] [Related]
12. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.
Ossendorp F; Mengedé E; Camps M; Filius R; Melief CJ
J Exp Med; 1998 Mar; 187(5):693-702. PubMed ID: 9480979
[TBL] [Abstract][Full Text] [Related]
13. Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus.
Arvin AM; Sharp M; Moir M; Kinchington PR; Sadeghi-Zadeh M; Ruyechan WT; Hay J
Viral Immunol; 2002; 15(3):507-16. PubMed ID: 12479399
[TBL] [Abstract][Full Text] [Related]
14. Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination.
Jenkins DE; Yasukawa LL; Bergen R; Benike C; Engleman EG; Arvin AM
J Immunol; 1999 Jan; 162(1):560-7. PubMed ID: 9886433
[TBL] [Abstract][Full Text] [Related]
15. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination.
Frey CR; Sharp MA; Min AS; Schmid DS; Loparev V; Arvin AM
J Infect Dis; 2003 Jul; 188(1):40-52. PubMed ID: 12825169
[TBL] [Abstract][Full Text] [Related]
16. Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine.
Vafai A
Vaccine; 1993; 11(9):937-40. PubMed ID: 8212841
[TBL] [Abstract][Full Text] [Related]
17. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.
Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D
Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809
[TBL] [Abstract][Full Text] [Related]
18. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects.
Giller RH; Winistorfer S; Grose C
J Infect Dis; 1989 Dec; 160(6):919-28. PubMed ID: 2555419
[TBL] [Abstract][Full Text] [Related]
19. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.
Zarling JM; Eichberg JW; Moran PA; McClure J; Sridhar P; Hu SL
J Immunol; 1987 Aug; 139(4):988-90. PubMed ID: 3497202
[TBL] [Abstract][Full Text] [Related]
20. Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes.
Sadzot-Delvaux C; Kinchington PR; Debrus S; Rentier B; Arvin AM
J Immunol; 1997 Sep; 159(6):2802-6. PubMed ID: 9300702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
